Processing

Please wait...

Settings

Settings

1. WO2020014460 - HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF

Publication Number WO/2020/014460
Publication Date 16.01.2020
International Application No. PCT/US2019/041373
International Filing Date 11.07.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
A61K 39/12 (2006.01)
A61P 31/14 (2006.01)
CPC
A61K 2039/60
A61K 2039/70
A61K 39/12
A61P 31/14
C12N 2760/18234
Applicants
  • SCHOLAR ROCK, INC. [US/US]; 620 Memorial Drive 2nd Floor Cambridge, MA 02139, US
Inventors
  • DATTA, Abhishek; US
  • CAPILI, Allan; US
  • SCHURPF, Thomas; US
  • MARTIN, Constance; US
  • DAGBAY, Kevin, B.; US
  • CHAPRON, Christopher; US
  • WAWERSIK, Stefan; US
  • LITTLEFIELD, Christopher; US
  • CARVEN, Gregory, J.; US
  • BUCKLER, Alan; US
  • LIN, Susan; US
  • JACKSON, Justin, W.; US
  • STEIN, Caitlin; US
  • AVERY, Andrew; US
  • COOPER, Anthony; US
  • SALOTTO, Matthew; US
Agents
  • CLARKE, Marcie, B.; US
  • BAI, Mei; US
  • BLAZESKI, George; US
  • BROWN, Ronald, E.; US
  • BOWLES, Anita, M.; US
Priority Data
62/696,75211.07.2018US
62/718,19613.08.2018US
62/737,53427.09.2018US
62/758,18009.11.2018US
62/810,26325.02.2019US
62/827,55201.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
(FR) INHIBITEURS DE TGFβ1 SÉLECTIFS SELON L'ISOFORME À AFFINITÉ ÉLEVÉE
Abstract
(EN)
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting ΤGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
(FR)
L'invention concerne des anticorps monoclonaux et des fragments de liaison à l'antigène de ceux-ci capables d'inhiber sélectivement ΤΟΡβ1 avec un pouvoir élevé. L'invention concerne également des compositions, des procédés et une utilisation thérapeutique associés.
Latest bibliographic data on file with the International Bureau